Drug Trial Radar · NCT07499050
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Jan 9, 2027
Study completion Jan 9, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.
Conditions
- Healthy Volunteers
- Overweight or Obesity
Interventions
RO7795081Drug
RO7795081 will be administered orally once a day.
PlaceboDrug
Placebo will be administered orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, Severity, and Causal Relationship to Treatment of Adverse EventsTime frame: Baseline to Safety Follow-Up (26 weeks)
- Incidence of Abnormal Clinical Laboratory Test FindingsTime frame: Baseline to Safety Follow-Up (26 weeks)
- Incidence of Abnormal Vital SignsTime frame: Baseline to Safety Follow-Up (26 weeks)
- Incidence of Abnormal Electrocardiogram (ECG) ResultsTime frame: Baseline to Safety Follow-Up (26 weeks)
- Incidence of Abnormal Psychiatry ParametersTime frame: Baseline to Safety Follow-Up (26 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanjing Gulou Hospital
Nanjing, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.